Announces Strategic Investment from GIBF2 and Launch of BV100 Clinical Program in China
Summary
Marc Gitzinger, Chief Executive Officer and founder of BioVersys: We are very pleased to announce this new strategic partnership with the highly regarded investment firm GIBF, which will serve to further expedite the clinical development of our lead asset BV100 in China. Resistance to antibiotics has become a leading cause of death and BV100 has started generating impressive clinical data, which we believe will make it a key asset in the treatment armamentarium of hospitals in China and around the world. We look forward to supporting BioVersys in its efforts to develop innovative anti-infective treatments in China.With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of supporting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.For further information please visit https://gibf-bio.com/enBioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. Derived from the companys two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.